Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
$INCY big call sweeps and M&A rumor earlier... should not this at least close green before weekend ? https://t.co/tmksTVa1X5
LONG $INCY! .... the BIO of this lawyer reads very sexy to my TAKEOVER Thesis! Does it not? ... EXCLUSIVELY ON M&A Transactions! ... https://t.co/o2vikrfLaZ
$LONG INCY - Today's sell off is a great Opportunity! Hiring these type of M&A lawyers you usually do when sale of the company is in the cards / in play. Dr. Lutz Angerer., serves as the head of the Corporate/M&A practice group in the Munich office and is a member of the…
Merck (MRK) is reportedly making strategic moves in the oncology sector, with significant interest in hedging with their own assets in the PDxV space. This follows discussions about the company's increased conviction on the PD1-VEGF dataset. Merck's recent $588 million acquisition deal, which lacks Phase 1 data, has sparked debate over the company's strategy. David Weinstock of Merck mentioned the company's receptiveness to innovative ideas, hinting at the LaNova deal as a key move to fill their pipeline post-pembro world.
